Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.

@article{Brandolini2015TargetingCO,
  title={Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.},
  author={Laura Brandolini and Loredana Cristiano and Alessia Fidoamore and Maria De Pizzol and Erica Di Giacomo and Tiziana Marilena Florio and Giuseppina Confalone and Angelo Galante and Benedetta Cinque and Elisabetta Benedetti and Pier Adelchi Ruffini and Maria Grazia Cifone and Antonio Giordano and Marcello Alecci and Marcello Allegretti and Annamaria Cimini},
  journal={Oncotarget},
  year={2015},
  volume={6 41},
  pages={43375-94}
}
In breast cancer it has been proposed that the presence of cancer stem cells may drive tumor initiation, progression and recurrences. IL-8, up-regulated in breast cancer, and associated with poor prognosis, increases CSC self-renewal in cell line models. It signals via two cell surface receptors, CXCR1 and CXCR2. Recently, the IL-8/CXCR1 axis was proposed as an attractive pathway for the design of specific therapies against breast cancer stem cells. Reparixin, a powerful CXCR1 inhibitor, was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…